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Abstract
Background: Androgens and androgen receptors (AR) regulate normal prostate development
and growth. They also are involved in pathological development of prostatic diseases, including
benign prostatic hyperplasia (BPH) and prostate cancer (PCa). Antiandrogen therapy for PCa, in
conjunction with chemical or surgical castration, offers initial positive responses and leads to
massive prostate cell death. However, cancer cells later appear as androgen-independent PCa. To
investigate the role of AR in prostate cell proliferation and survival, we introduced a vector-based
small interfering RNA (siRNA). This siRNA targeted 5'-untranslated region of AR mRNA for
extended suppression of AR expression in androgen-sensitive human prostate LNCaP cells.
Results: The siRNA design successfully suppressed endogenous AR expression, as revealed by
western blotting and immunofluorescence staining in LNCaP cells. LNCaP cells did not proliferate
in the absence of AR and underwent apoptosis, based on elevated phospho-Histone H2B
expression and higher number of apoptotic body as compared to control cells.
Conclusion: We demonstrated that AR is vital for prostate cell proliferation and survival in this
androgen-sensitive prostate cell line. These results further strengthen the hypothesis that AR can
be a therapeutic target for treating androgen-sensitive stages of PCa. Unlike antiandorgens,
however, siRNA targeting AR provides a direct inactivation of AR function through the suppression
of AR protein expression.
Background
Androgens are critical for the development and growth of
normal prostate. They also are responsible for the devel-
opment of prostate diseases, including benign prostatic
hyperplasia (BPH) and prostate cancer (PCa). Androgen
receptors (AR) transduce androgen signals in prostate cells
to regulate the physiological and pathological develop-
ment of the gland [1]. It is classically characterized that
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after ligand binding [mainly 5α-dihydrotestosterone (5α-
DHT)] the ligand-AR receptor complex with associated
proteins translocates into the nucleus, binds to the con-
sensus sequence of androgen response elements (AREs)
[2], and regulates androgen responsive genes (ARGs)
expressions [3]. Conditions that activate abnormal AR
trans-activation through AR mutations [4,5], amplifica-
tion of AR [6], or androgen-independent signaling path-
ways [7,8] can lead to or be a result of the development of
prostatic diseases or androgen refractory PCa.
Clinically, androgen ablation therapy is used to reduce AR
ligand production or to block AR-mediated signaling. Fin-
asteride, a 5α-reductase type 2 inhibitor, has been used for
treating patients with BPH. Finasteride slows the progres-
sion of BPH by suppressing 5α-DHT synthesis [9]. Andro-
gen ablation therapy for PCa has been achieved using
compounds called antiandrogens. Antiandrogens com-
pete with 5α-DHT for AR binding and intend to block AR-
mediated signaling. Antiandrogens are classified, accord-
ing to their chemical structure, as either steroidal antian-
drogens (ie, cyproterone acetate or medroxyprogesterone
acetate) or non-steroidal anti-androgens [ie, nilutamide
(Anandron™), flutamide (Eulexin™), and bicalutamide
(Casodex™)] [10]. Unfortunately, essentially all of the
patients who show initially favorable responses to the
androgen blockade eventually become refractory to this
treatment [11].
Abruption of AR signaling has been examined in experi-
mental models to investigate AR-mediated prostate cell
physiology and pathophysiology. An antisense oligonu-
cleotide [12], a hammerhead robozyme [13], and micro-
injection of an AR neutralizing antibody [14] have been
designed to suppress AR expression or block AR-mediated
signaling in in vitro models. The advance of RNA interfer-
ence (RNAi) technology provides a tool to suppress gene
expression through post-translational gene silencing
(PTGS) [15]. This technology utilizes duplex small inter-
fering RNAs (siRNAs) of about 19–23 nucleotides to sup-
press the expression of the homologous gene [16,17].
Wright et al. reported a successful use of a synthetic dou-
ble-stranded (ds) siRNA to suppress endogenous AR
expression in LNCaP cells [18]. In this study, we estab-
lished a vector-based siRNA plasmid construct targeting
the 5'-untranslated region (5'-UTR) of the AR in the same
prostate cell line. We successfully achieved AR silencing in
LNCaP cells, and further demonstrated that these cells
could neither proliferate nor survive in the absence of the
AR. We concluded that AR signaling is required for both
prostate cell proliferation and survival, at least in andro-
gen-sensitive states. Specific blocking of AR expression
and AR-mediated signaling is required for a successful
androgen blockade in patients with prostate diseases. In
addition, the vector-based AR silencing design provides a
tool to study AR-associated genomic and non-genomic
effects and to identify potential pathways that cross-talk
with AR.
Results and discussion
To identify the role of AR in AR-positive, androgen-sensi-
tive LNCaP cells, we designed a vector-based siRNA plas-
mid construct to achieve "long-term" AR silencing. This
construct contained the U6 promoter-driven sense and
antisense strands of AR siRNA that have a termination sig-
nal consisting of 6 thymidines. This construct also
included a constitutively expressed CMV promoter-driven
green fluorescence protein (GFP), designated pSiAR-EGFP
(Fig. 1). Because there is an adverse effect on androgen-
sensitive prostate cell proliferation in the absence of the
AR [12,14,18], the inclusion of the CMV promoter-driven
GFP expression could be used to select and enrich AR-neg-
ative LNCaP cells following transfection. A construct,
named pSiCon-EGFP, was established with a scrambled
AR target sequence and served as a control. At 16 hours
following transfection, GFP was expressed and detectible
under a fluorescence microscope (data not shown).
Plasmid siRNA construct targeting 5'-UTR of AR mRNA 
suppressed AR expression in LNCaP cells
To determine whether the pSiAR-EGFP construct was
capable of expressing siRNA, thereby suppressing AR
expression in LNCaP cells, cells were transfected with
pSiAR-EGFP or with pSiCon-EGFP construct. AR expres-
sion was monitored by staining these cells with mouse-
anti-human AR monoclonal antibody. Immunocyto-
chemical staining of LNCaP cells showed that portions of
cells transfected with pSiAR-EGFP plasmid had no detect-
ible AR expression, whereas cells transfected with pSiCon-
EGFP continued to show AR expression in all cells (Figure
2A). However, at 2 weeks following transfection, there
was no detectible GFP-positive or AR-negative LNCaP
cells in the pSiAR-EGFP transfected group (data not
shown). This suggested that either the cells lost their trans-
fected pSilencer plasmids, or that the cells receiving the
pSiAR-EGFP could, in fact, not survive in the absence of
the AR.
To demonstrate that GFP can be used as a marker for
selecting AR-negative LNCaP cells, pSiAR-EGFP or pSi-
Con-EGFP transfected cells were trypsinized 24 hours fol-
lowing transfection. GFP-positive cells were collected
through a cell sorter to determine AR protein expression.
Western blot analysis showed no detectible AR protein
expression in GFP-positive cells transfected with pSiAR-
EGFP. However, GFP-positive cells receiving the control
pSiCon-EGFP construct continued to express AR protein
(Figure 2B). This result demonstrated that GFP positive
cells are AR negative cells.Cancer Cell International 2005, 5:8 http://www.cancerci.com/content/5/1/8
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The use of 5'-UTR as a target for designing siRNA has been
discouraged, because UTR binding proteins and/or trans-
lation initiation complexes may interfere with siRNA
endonuclease complex binding [19]. There are multiple
mutations in cases of PCa being identified throughout the
AR coding regions [20-22]. This makes the selection of the
AR coding region for siRNA design possibly inappropriate
and insufficient to block the expression of mutated AR in
PCa patients. We selected three 5'-UTR regions of the AR
for our siRNA design; only the region between -25 to -7 bp
could successfully suppress AR expression in LNCaP cells
(data not shown). Our results further demonstrated that
siRNA's efficacy of suppressing gene expression varies
from one region to another, due to target sequence struc-
tures [23].
LNCaP cells required AR to support cell proliferation
To determine LNCaP cell proliferative capability in the
absence of AR, cell proliferation with and without cell
sorting was performed following the silencer construct
transfection. When cell proliferation was performed with-
out cell sorting, during a 9 day period the pSiAR-EGFP
transfected LNCaP cells consistently proliferated slower
than the parental cells and the pSiCon-EGFP transfected
cells (Figure 3A). After 9 days in culture, both parental and
control cells reached confluence. The reduced cell
A vector-based plasmid construct for suppression of AR expression in LNCaP cells Figure 1
A vector-based plasmid construct for suppression of AR expression in LNCaP cells. (A) Two single-stranded oligo-
nucleotides were synthesized consisting of a 19 nucleotide of -25 to -7 bp 5'-UTR of the AR mRNA separated by a short loop 
sequence from the reverse complement of the same sequence. The sense strand of synthesized oligonucleatides was ended 
with five thymidines as termination signal. The annealed ds DNA contained Bgl II and Sfi I restriction at its 5' and 3' end of the 
oligonucleotides, respectively. (B) Schematic drawing of the pSiAR-EGFP vector. The expression construct was designed to 
expression AR siRNA driven by U6 promoter for suppression of endogenous AR expression in mammalian cells. The expres-
sion construct also contained EGFP driven by the CMV promoter constitutive expression of GFP in target cells.
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Suppression of endogenous AR expression in LNCaP cells using the pSiAR-EGFP expression construct Figure 2
Suppression of endogenous AR expression in LNCaP cells using the pSiAR-EGFP expression construct. LNCaP 
cells were transfected with either the pSiAR-EGFP or the pSiAR-EGFP construct using the Lipofectemine 2000 protocol. (A) 
Immunocytochemical detection of AR expression in transfected cells. To determine AR expression in LNCaP cells, following 
transfection, cells were stained with mouse anti-human AR monoclonal antibody (1:100 dilution) followed by AlexaR FluorR 
594 conjugated goat anti-mouse IgG secondary antibody (2 mg/ml) incubation. The AR staining was detected by fluorescent 
microscopy (BX51, Olympus). The images were composite between the red with the positive in AR staining with the phase-
contract from the same field. Suppression of endogenous AR expression was demonstrated by the absence of red fluorescence 
staining as indicated by arrows. DAPI staining showed the number of cells in the same field. (B) Western blot analysis of AR 
expression in pSiAR-EGFP and control transfected cells. At 7 days following transfection, both GFP-positive and GFP-negative 
cells were collected through cell sorter; and cells were lysed to prepare cellular protein extracts. Aliquots of 20 µg total cellu-
lar protein were loaded into Tris-HCl gels and transferred to PDVF membranes. The AR expression was determined by incu-
bating with mouse anti-human AR monoclonal antibody (1:500) followed by the HRP-conjugated anti-mouse IgG (1:125,000) 
secondary antibody incubation. Immunoreactive signals were detected using ECL. Levels of β-actin expression was also deter-
mined in each sample and used as protein loading control.
AR
β-actin
GFP +- +-
Plasmid pSiAR pSiCon
A
B
pSiAR pSiCon
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Suppression of LNCaP cell proliferation in the absence of endogenous AR Figure 3
Suppression of LNCaP cell proliferation in the absence of endogenous AR. LNCaP cells were seeded in tissue cul-
ture plates and transfected with a mixture of either pSiAR-EGFP or pSiCon-EGFP plasmid construct with Lipofecamine 2000 in 
OPTI-MEM. (A) Cell proliferation without separation of GFP-positive and negative cells. At 24 hours following transfection, 
cells were trypsinized and distributed into each well (1,000 cells/well) of 96-well tissue culture plates in the presence the com-
plete medium. Cell proliferation was determined using the XTT assay kit for a period of 9 days; data from days 11 and 14 were 
not included since parental and pSiCon-EGFP transfected LNCaP cells reached confluence after day9. (B) LNCaP cell prolifera-
tion following enrichment of GFP-positive cells. At 24 hours after transfection, cells were trypsinized and EGFP-positive cells 
were collected through the MoStar cell sorting system. GFP-positive cells were seeded into each well (1,000 cells/well) of 96-
well plates for cell viability assay. Cell proliferation was determined for a period of 14 days. Data were calculated as absorbance 
at days following transfection normalized to the absorbance at the day of cell sorting, and presented as fold induction in 
absorbance. LNCaP cells transfected with pSiCon-EGFP plasmid construct were used as the AR-positive control. * represents 
significant statistical difference between LNCaP cells with and without AR (P < 0.001). Each time point represents the mean ± 
SEM from 3 independent experiments.
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proliferation in pSiAR-EGFP transfected cells might reflect
that cells receiving the AR siRNA construct failed to prolif-
erate in the absence of AR.
To confirm that AR signaling is required for LNCaP cell
proliferation, GFP enriched LNCaP cells were collected
through cell sorting at 24 hours following transfection.
LNCaP cells transfected with the pSiCon-EGFP construct
continued to grow over the entire experimental period
(Figure 3B). This indicates that the silencer control con-
struct did not affect cell proliferation. However, pSiAR-
EGFP transfected LNCaP cells (GFP-positive, AR-negative)
failed to proliferate (Figure 3B), indicating that the andro-
gen-sensitive prostate cells require AR for proliferation.
Suppression of AR expression and inactivation of AR func-
tion in prostate cells has been achieved through the use of
an antisense oligonucleotide [12,24], a hammerhead
robozyme [13], and a synthesized ds siRNA duplex [18] to
target AR mRNA. Microinjection of an AR neutralizing
antibody has also been reported to block AR-mediated
signaling in LNCaP cells [14]. Recently, the use of vector-
based siRNA targeting AR has been reported to study the
involvement of AR signaling in vitamin D-suppressed
prostate cell growth [25]. These published approaches
were intended for transient gene silencing in target cells,
and provided short term elimination of AR expression. All
of the currently published results are consistent with our
observations that disruption of AR signaling adversely
affects androgen-sensitive LNCaP cell proliferation.
LNCaP cells required AR to maintain survival
To determine whether LNCaP cells could survive without
AR, we determined the levels of phospho-histone H2B
expression and the number of apoptotic body following
AR silencing. Histon H2B phosphorylation has been
shown to be uniquely associated with apoptosis, specifi-
cally in apoptosis-induced chromatin condensation in
mammalian cells [26]. Its expression significantly
increases in cells undergoing apoptosis [27]. Using West-
ern blot analysis, phospho-histone H2B expression was
quantitated in LNCaP cells transfected with either pSiAR-
EGFP or pSiCon-EGFP. There was no detectible phospho-
histone H2B signal in pSiAR-EGFP or control transfected
cells at 4 days after transfection (data not shown). Six days
following pSiAR-EGFP transfection, however, elevated
levels of phospho-histone H2B expression were detected
in AR negative LNCaP cells. At that time, there was no
detectible phospho-histone H2B in the pSiCon-EGFP
transfected LNCaP cells (Figure 4).
To prove that AR signaling is required for LNCaP cell sur-
vival, the number of cells undergoing apoptosis (demon-
strated by the presence of apoptotic bodies) was
determined in cells transfected with pSiAR-EGFP and
control constructs (Figure 5). The average number of
apoptotic bodies in pSiAR-EGFP transfected cells was
52.89 per 1,000 cells, versus 6.53 in 1,000 pSiCon-EGFP
transfected cells (Table 1). The transfection efficiencies for
each vector were not statistically significant – pSiAR-EGFP
was 17.0% and pSiCon-EGFP was 22.9% (Table 1). When
the number of apoptotic bodies was corrected for transfec-
tion efficiency, ABI was 296.2 for pSiAR-EGFP and 29.2
for pSiCon-EGFP transfected cells (Table 1). The ABI was
statistically higher in pSiAR-EGFP transfected cells versus
pSiCon-EGFP transfected cells. These results demon-
strated that LNCaP cells lacking AR would go through the
process of apoptosis.
To demonstrate that LNCaP cells could survive with tran-
sient suppression of AR, we also performed AR protein
expression knockdown using a synthesized, pooled ds
siRNA, siRNA SMARTpool AR® (Upstate). This siRNA pool
suppressed a majority (greater than 95%) of AR protein
expression in LNCaP cells at 16 hours after transfection, as
compared to cells transfected with a non-specific control
pool. The cells maintained suppressed levels of AR protein
expression for at least 72 hours following transfection.
They resumed AR expression, to 20–30% of normal levels,
after 72–96 hours post-transfection (data not shown).
LNCaP cells could survive in the absence of AR for at least
3–4 days, as indicated by the lack of detectable phospho-
histone H2B signals at 96 hours following the pSiAR-
EGFP transfection (data not shown). Due to the transient
nature of the use of antisense oligonucleotides, hammer-
head robozymes, ds siRNA duplexes, and microinjected
Elevated expression of phospho-histone H2B S(14) in AR- knockdown LNCaP cells Figure 4
Elevated expression of phospho-histone H2B S(14) in 
AR-knockdown LNCaP cells. LNCaP cells were either 
transfected with pSiAR-EGFP or pSiCon-EGFP plasmid con-
struct. On day 6 after transfection, cells were harvested. Cel-
lular proteins were extracted using acid extraction method, 
electrophoresized through gradient Tris-HCl gels, and elec-
troblotted onto PVDF membranes. Levels of phospho-his-
tone H2B expression was detected by an immunoassay 
procedure.
Phospho-Histone
H2B (Ser14)
pSiCon pSiAR
β-actinCancer Cell International 2005, 5:8 http://www.cancerci.com/content/5/1/8
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neutralizing antibodies against AR, cell survival in the
extended absence of AR could not be assessed. Using the
combination of the vector-based siRNA delivery and
enrichment of AR-negative cells through the selection of
GFP-positive cells enabled us to study cell behavior in the
absence of AR over an extended time-period.
Antiandrogens are used to prevent the acquisition of a
transcriptionally active conformation of the AR. The
induction of apoptosis in prostate cells treated with bical-
utamide has been observed [28]. However, several reports
also indicate that in the presence of bicalutamide, prostate
cells survive in culture [29], regain cell growth after an
extended period of exposure to the antiandrogen [30,31],
and become a more invasive phenotype [32]. Bicaluta-
mide can also act as an AR agonist, resulting in the stimu-
lation of AR trans-activation [33]. Furthermore, it has been
indicated that bicalutamide may support prostate cell sur-
vival and progression through selection of cells with AR
mutations [34] or cells with elevated expression of growth
factors [35]. These mutations generate receptors that
respond to other steroids and antiandrogens by increased
trans-activation [4]. These results suggest that
antiandrogens may be insufficient to block AR signaling
through multiple candidate pathways.
The potential use of RNAi technology has been investi-
gated in the field of gene therapy [36,37]. Targeting AR
suppression using RNAi might be more efficient and spe-
cific than using antiandrogens to inactivate AR trans-acti-
vation and turn off ARGs expression. LNCaP cells
potentially consist of multiple cell lineages, due to the
development of multiple sublines from the original
LNCaP cells [38-40]. Although all LNCaP cells transfected
by the AR siRNA construct could neither proliferate nor
survive in the absence of the AR in this study, we do not
have information regarding specific sub-populations that
may be more susceptible to transfection and sensitive to
the absence of the AR. The development of a more effi-
cient delivery system, such as the lentiviral-based gene
delivery system [41], may allow for further study of AR sig-
naling in multiple prostate cell lines.
Conclusion
We concluded that all PCa cells, at least in the androgen-
sensitive and AR-positive stages, require AR for continued
proliferation and survival. The identification of AR path-
way and ARG(s) that transduce androgen signaling might
provide a specific target to block androgen-activated, AR-
mediated prostate cell growth. Specifically targeting AR or
its downstream signaling molecules potentially will be
effective in achieving total androgen blockade. With the
development of "long-term" siRNA and efficient delivery
systems in vivo, we may achieve a total AR blockade in the
prostate, thereby improving treatment for patients with
prostate diseases.
Methods
Establishment of AR silencer plasmid constructs
To establish a siRNA plasmid construct with fluoresce
selection marker, a multiple cloning site (MCS) was
excised from the pSE380 (Invitrogen) using Bcl I and Hind
Elevated number of apoptotic LNCaP cells transfected  pSiAR-EGFP construct Figure 5
Elevated number of apoptotic LNCaP cells trans-
fected pSiAR-EGFP construct. Apoptotic bodies in 
LNCaP cells transfected with control vector pSiCon-EGFP 
(A) and pSiAR-EGFP (B). Following transfection with these 
plasmid constructs, LNCaP cells were collected through cen-
trifugation, fixed in neutralized formalin, and encased in 
agrose blocks. Cell blocks were paraffin-embedded, sec-
tioned, deparaffinized, rehydrated, and stained with hematox-
ylin. Apoptotic bodies which showed condensed and/or 
cleaved nucleus were counted from random fields and 
numerical data are shown in Table 1.Cancer Cell International 2005, 5:8 http://www.cancerci.com/content/5/1/8
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III. The MCS containing fragment was subcloned into Bam
HI and Hind III linearized pSilencer 2.1-U6 hygro vector
(Ambion) to obtain pSilencer 2.1-U6 MCS hygro. The
IRES2-EGFP fragment coding for GFP was excised from
pIRES2-EGFP (BD Biosciences Clontech) using Bgl II and
Afl II. This excised fragment was then subcloned into the
pSilencer 2.1U6 MCS hygro linearized with Bcl I and Sal I
in the presence of a short adaptor containing Afl I site on
its 5'ends and Sal I site on its 3'ends. This established plas-
mid was named pSilencer 2.1-U6-IRES2-EGFP. To create
the silencer construct targeting AR, two complementary
strands of oligonucleotides targeting -25 to -7 bp
upstream from the ATG transcription start codon of the
AR (GenBank accession number M20132; Figure 1A) with
Bgl II and Sfi I sites on its 5' and 3' ends, respectively, was
synthesized and annealed. The ds oligonucleotide was
cloned into Bam HI and Hind III linearized pSilencer 2.1-
U6-IRES2-EGFP. The 19-nucleotide AR target sequence is
indicated in the sense strand of the synthesized ds DNA.
The U6 promoter-driven siRNA expresses the sense and
antisense strands of AR siRNA [42] that have a termina-
tion signal consisting of 6 thymidines [43].
Since the SV40 promoter could not provide sufficient lev-
els of GFP expression in LNCaP cells for monitoring suc-
cessful transfection (data not shown), the SV40 promoter
was replaced by cymagalovirus (CMV) promoter. The
CMV promoter was excised from pIRES2-EGFP with Nsi I
and Xho I, and ligated into Aat II and Xho I linearized pSi-
lencer 2.1-U6-IRES2-EGFP. The final construct was desig-
nated pSiAR-EGFP (Figure 1B). Control construct also was
established by cloning an annealed ds DNA fragment with
a scrambled 19-nucleotide AR target sequence, named
pSiCon-EGFP. The scrambled sequence was subjected to
Blast search to ensure no match to any known transcript.
LNCaP cell culture, transfection, and selection of cells 
transfected with the AR silencer expression construct
LNCaP cells were purchased from ATCC (CRL-1740).
They were cultured and maintained in complete growth
medium consisting of RPMI1640 (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS), 100 unit/ml
penicillin, and 100 µg/ml streptomycin (Invitrogen) in a
humidified atmosphere containing 5% CO2  at 37°C.
Transfection of cells with the plasmid silencer constructs
was performed in either 60 or 100 mm tissue culture
plates using Lipofecamine 2000 (Invitrogen) when cells
reached 80–90% confluence. Briefly, for transfection in
100 mm plates, 24 µg of plasmid DNA and 60 µl of Lipof-
ecamine 2000 transfection reagent were diluted separately
in 1.5 ml of OPTI-MEM (Invitrogen). They were then
combined, and incubated at room temperature for 20
minutes. The mixture was added to LNCaP cells in the
presence of 10 ml OPTI-MEM (Invitrogen). The serum
free medium was replaced by the complete growth
medium 4–6 hours following transfection. The day of
transfection was defined as day 0. To select cells that
received the silencer constructs, LNCaP cells were
trypsinized at 24 hours after transfection (day 1). GFP-
positive LNCaP cells were collected using MoStar cell sort-
ing system. For determining the apoptotic index, transfec-
tion efficiency was calculated at 24 hours after
transfection. A total of 1,000 cells were randomly selected
under a microscope equipped with fluorescence filters
from 2–3 fields. The percentages of cells expressing GFP
were termed "transfection efficiency". The transfection
efficiency average was calculated from three independent
experiments for each plasmid transfection.
Immunocytochemical staining of AR in LNCaP cells
To demonstrate that the AR silencer plasmid construct
could suppress AR expression in LNCaP cells, at 24 hours
post-transfection the cells were re-seeded onto cover slips
in 24-well tissue culture plates at the density of 2,000
cells/well. Cells were incubated overnight for adherence.
They were sequentially fixed in methanol for 10 minutes
and acetone for 1 minute. Cells were then permeabilized
with 0.2% triton-X-100 (Simga) in 1x phosphate buffered
saline (PBS) at room temperature for 20 minutes. Follow-
ing incubation with 10% goat serum in 1x PBS to block
non-specific binding, cells were incubated for another 1
hour with mouse anti-human AR monoclonal antibody
(1:100; NOVOCastra) in 1x PBS containing 10% goat
serum. Following three washes with PBS supplemented
Table 1: Apoptotic body indices in pSiAR-EGFP and pSiCon-EGFP transfected LNCaP cells
# of apoptotic bodies (per 1,000)a Transfection efficiency (%) Apoptotic body indexc
Mean + S.D. Mean + S.D. Mean + S.D.
pSiAR-EGFP 52.89 ± 22.12b 17.0 ± 3.45 296.2 ± 78.2b
pSiCon-EGFP 6.53 ± 2.85 22.9 ± 2.84 29.2 ± 15.4
a The number of apoptotic bodies were was determined by counting 1,000 cells from each of 3 independent hematoxylin stained slides.
b Significant difference between pSiAR-EGFP and pSiCon-EGFP transfected cells (p < 0.05).
c Apoptotic body indices were calculated after normalizing to transfection efficiency.Cancer Cell International 2005, 5:8 http://www.cancerci.com/content/5/1/8
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with 0.5 mM CaCl2 and MgCl2, cells were incubated with
Alexa Fluor® 594-conjugated goat anti-mouse IgG (1:200;
Molecular Probes) secondary antibody. For nuclei stain-
ing, cells were incubated with 0.1 µg/ml 4',6'-diamidino-
2-phenylindole hydrochloride (DAPI) at room tempera-
ture for 20 minutes. Images were captured by fluorescent
microscopy (BX51, Olympus) equipped with the SPOT
software (Diagnostic Instrument).
Protein extraction and Western blot analysis
Western blot analysis was performed to determine AR lev-
els and phospho-histone H2B expression in LNCaP cells
transfected with the silencer constructs. To determine lev-
els of AR expression, pSiAR-EGFP and control transfected
GFP-positive LNCaP cells were collected through cell sort-
ing. They were lysed with cell lysis buffer consisting of 5
mM EDTA, 0.5% Triton-X-100, and 0.1 mM phenylmeth-
ylsulphonylfluoride (PMSF) in 1x PBS at 1 µl/104 cells.
Total cellular extracts were collected following centrifuga-
tion. Protein concentrations were determined by bicin-
choninic acid (BCA) protein assay kit (Pierce). Aliquots of
20 µg of the protein extracts were separated on 10% Tris-
HCl gel (Bio-Rad). Proteins were then transferred to PVDF
membranes (Bio-Rad). AR protein was detected by incu-
bating the membranes with the mouse anti-human AR
monoclonal antibody (1: 500) at room temperature for 2
hours. This was followed by the horseradish peroxidase
(HRP)-conjugated anti-mouse IgG (1:125,000; KPL) sec-
ondary antibody incubation at room temperature for
another hour. Immunoreactive protein was detected using
the enhanced chemiluminescent (ECL) reagent (Pierce)
according to the manufacturer's protocol.
To determine histone H2B phosphorylation levels in
LNCaP cells in the absence of AR protein, cells were trans-
fected with either pSiAR-EGFP or control construct as
described. Cellular proteins were extracted with acid
extraction buffer consisting of 10 mM Hepes (pH 7.9), 1.5
mM MgCl2, 10 mM KCl, 0.5 mM DTT, and 1.5 mM PMSF
in the presence of 0.2 M hydrochloric acid. This was com-
pleted according to procedures provided by the antibody
supplier (Upstate). Soluble proteins were collected from
supernatants after centrifugation at 11,000 × g for 10 min-
utes. Proteins were then dialyzed overnight against dis-
tilled water. Aliquots of 30 µg proteins were prepared
from each sample, separated on 4–20% gradient Tris-HCl
gels (Bio-Rad), and transferred to PVDF membranes. After
blocking non-specific binding, the membranes were incu-
bated overnight with rabbit anti-phospho-histone H2B
S(14) antibody (1:500; Upstate) at 4 °C. This was fol-
lowed by a HRP-conjugated anti-rabbit IgG (1:10,000;
Cell Signaling) secondary antibody incubation followed
by ECL detection.
Cell proliferation assay
Cell proliferation assay was determined in pSiAR-EGFP
and pSiCon-EGFP transfected LNCaP cells. At 24 hours
following transfection, they were either directly seeded
into tissue culture plates or subjected to cell sorting to col-
lect GFP-positive cells prior to cell seeding. Cells were
seeded into 96-well plates at 1,000 cells/well. Cell prolif-
eration was determined using XTT cell proliferation assay
kit (Roche) following the manufacturer's protocol. Prolif-
eration was evaluated for a period of 14 days. Data
analysis of three independent transfections of cells sorted
for GFP-positive cells was performed as previously
reported [44]. Results were presented as mean ± standard
error of means (SEM).
Determination of apoptotic index in cell blocks
To characterize whether LNCaP cells undergo apoptosis in
the absence of AR, numbers of apoptotic bodies were
quantitated in LNCaP cells transfected with pSiAR-EGFP
and control silencer constructs. Transfected cells were
tripsinized and centrifuged at 400 × g for 5 minutes to col-
lect the cells. The cell pellets were fixed in 10% formalin
for at least 24 hours. They were then mixed with drops of
warm 2% agarose in order to form cell-agarose blocks. The
cell blocks were paraffin embedded, cut at 4–6 µm,
mounted on microscope slides, and baked at 55 °C over-
night. The slides were deparaffinized, rehydrated to water,
and stained by hematoxylin. Apoptotic bodies were quan-
titated under a bright field microscope at 400× magnifica-
tion. Apoptotic bodies were defined as small, roughly
spherical or ovoid cytoplasmic fragments, some of which
contained nuclear fragments [45]. The density of apop-
totic cells was determined by counting 1,000 cells from
each transfection. Quantitative analyses of apoptotic
changes were recorded as apoptotic body indices (ABI, the
number of apoptotic cells/transfection efficiencies).
Statistical Analysis
For statistical analysis, data were presented as mean and
SEM from at least 3 independent experiments. Statistical
significance was determined when P < 0.05. Student t-test
was used for comparing two treatment groups.
Abbreviations
5α-DHT: 5α-dihydrotestosterone; AR: androgen receptor;
ARE: androgen response element; ARG: androgen
response gene; RNAi: RNA interference; siRNA: small
interfering RNA.
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